


# Resistance against Membrane-Inserting MmpL3 Inhibitor through Upregulation of MmpL5 in *Mycobacterium tuberculosis*

Ming Li,<sup>a</sup> Samuel Agyei Nyantakyi,<sup>b\*</sup> Mei-Lin Go,<sup>b</sup>  Thomas Dick<sup>c,d,e,f</sup>

<sup>a</sup>Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

<sup>b</sup>Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore

<sup>c</sup>Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

<sup>d</sup>Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA

<sup>e</sup>Department of Medical Sciences, Hackensack Meridian School of Medicine, Nutley, New Jersey, USA

<sup>f</sup>Department of Microbiology and Immunology, Georgetown University, Washington, DC, USA

**ABSTRACT** Spiroketal indolyl Mannich bases (SIMBs) present a novel class of membrane-inserting antimycobacterials with efficacy in a tuberculosis mouse model. SIMBs exert their antibacterial activity by two mechanisms. The indolyl Mannich base scaffold causes permeabilization of bacteria, and the spiroketal moiety contributes to inhibition of the mycolic acid transporter MmpL3. Here, we show that low-level resistance to SIMBs arises by mutations in the transcriptional repressor MmpR5, resulting in upregulation of the efflux pump MmpL5.

**KEYWORDS** MmpL3, MmpR5, MmpL5, indolyl Mannich bases

The membrane is an attractive but underexplored target in the discovery of novel antimycobacterials (1, 2). Amphiphilic indolyl Mannich bases were shown to insert into and permeabilize the mycobacterial membrane, thus killing both growing and nongrowing bacilli (3). Consistent with their membrane-disrupting mechanism of action, resistance mutants could not be isolated (3). Incorporation of a spiroketal moiety in the Mannich base caused a 10-fold increase in potency (4). Interestingly, mutants resistant to the spiroketal analogs could be isolated and mapped to the mycolic acid transporter MmpL3 (5). Biochemical, metabolic, computational, and structure-activity relationship analyses revealed that the potency improvement was caused by the acquisition of a second mechanism of action due to the inclusion of the spiroketal moiety (5). In addition to permeabilizing the membrane, spiroketal analogs of the indolyl Mannich bases (SIMBs) inhibit the flippase activity of the transmembrane MmpL3 protein and, hence, the transport of mycolic acids from the cytoplasm to the periplasmic space (5). Thus, SIMBs are novel dual-mechanism antibacterials, disrupting the integrity of the bacterial cell membrane and blocking the transport of an essential cell wall component by inhibiting a transmembrane transporter (5). Consistent with this dual mechanism, missense mutations at the binding site of SIMBs on MmpL3 reverted the 10-fold potency increase achieved by the addition of the spiroketal moiety ( $\text{MIC}_{90} = 1 \mu\text{M}$ ) back to that observed for nonspiroketal Mannich bases ( $\text{MIC}_{90} = \sim 10 \mu\text{M}$ ), which act only by disrupting membrane integrity (5). Thus, the membrane-permeabilizing mechanism endowed by the amphiphilic indolyl Mannich base scaffold of SIMBs ensures that these compounds retain appreciable activity even after bacteria have acquired resistance to the second, MmpL3-related mechanism (5). Importantly, the lead compound of these dual-mechanism SIMBs, termed SIMB lead or SIMBL (9-[(6-methoxy-1-octyl-1*H*-indol-3-yl)methyl]-1,5-dioxo-9-azaspiro[5.5]undecane),

**Citation** Li M, Nyantakyi SA, Go M-L, Dick T. 2020. Resistance against membrane-inserting MmpL3 inhibitor through upregulation of MmpL5 in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 64:e01100-20. <https://doi.org/10.1128/AAC.01100-20>.

**Copyright** © 2020 Li et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Mei-Lin Go, [meilin.go@nus.edu.sg](mailto:meilin.go@nus.edu.sg), or Thomas Dick, [thomas.dick@hmm-cdi.org](mailto:thomas.dick@hmm-cdi.org).

\* Present address: Samuel Agyei Nyantakyi, Department of Neuroscience, Karolinska Institute, Stockholm, Sweden.

**Received** 29 May 2020

**Returned for modification** 3 September 2020

**Accepted** 16 September 2020

**Accepted manuscript posted online** 21 September 2020

**Published** 17 November 2020

**TABLE 1** MIC<sub>90</sub> of SIMBL for wild-type and SIMBL-resistant *M. tuberculosis* and *M. bovis* BCG strains and polymorphisms in *mmpR5*

Strain	MIC <sub>90</sub> (μM) <sup>a</sup>	Mutation	
		<i>mmpR5</i> <sup>b</sup>	Other genes <sup>c</sup>
<i>M. tuberculosis</i> wild type	1.0		
<i>M. tuberculosis</i> M1	3.9	A202G/S68G	Rv0907, C1190A/T397K
<i>M. tuberculosis</i> M2	4.0	G73T/G25C	
<i>M. bovis</i> BCG wild type	1.0		
<i>M. bovis</i> B1	4.2	Ins68T/truncation	BCG_2955, Ins2684C/truncation

<sup>a</sup>MIC<sub>90</sub> is the concentration of SIMBL required to inhibit 90% of bacterial growth in broth culture compared to an untreated drug-free control. Means of three independent determinations are shown. Synthesis of the spiroketal indolyl Mannich base lead compound SIMBL (9-[(6-methoxy-1-octyl-1*H*-indol-3-yl)methyl]-1,5-dioxo-9-azaspiro[5.5]undecane) was described previously (4).

<sup>b</sup>*mmpR5*, Rv0678 in *M. tuberculosis* and BCG\_0727 in *M. bovis* BCG.

<sup>c</sup>Polymorphisms in other genes detected by whole-genome sequencing.

showed efficacy in a mouse model of tuberculosis, hence providing *in vivo* proof of concept for this novel approach (4). Taken together, prior work identified SIMBL as a promising lead antimycobacterial with a novel dual mechanism of action, bactericidal activity against growing and nongrowing drug-tolerant bacilli, and efficacy in a tuberculosis mouse model (3–5).

In this study, we asked whether genetic resistance to SIMBL may also emerge via non-MmpL3-related indirect mechanisms. In the previous target deconvolution work, we employed high concentrations (4× and 8× MIC<sub>90</sub>; broth MIC<sub>90</sub> = 1 μM) of SIMBL for the selection of spontaneous resistance mutants, delivering exclusively on-target missense mutations in *MmpL3* with a frequency of 10<sup>−8</sup>/CFU (5). To identify additional, lower-level, off-target mechanisms of resistance to SIMBL, we repeated mutant selection with *Mycobacterium tuberculosis* H37Rv (ATCC 27294) as described in reference 5 but on Middlebrook 7H10 agar containing a lower concentration (3× MIC<sub>90</sub>; 3 μM) of SIMBL. Plating of 5 × 10<sup>8</sup> bacteria resulted in four resistant colonies that were restreaked on SIMBL-containing agar for confirmation of resistance and colony purification. Discrete colonies were then cultured, and MIC<sub>90</sub> values of SIMBL in Middlebrook 7H9 broth were determined as described (6). Two strains showed a 10-fold increase in MIC<sub>90</sub>, and two strains showed a 4-fold increase in MIC<sub>90</sub>. Targeted Sanger sequencing of *mmpL3* revealed that the two higher-level resistance mutants harbored missense mutations in *mmpL3*, T959C/L320P and G1772T/S591I, as reported previously (5), whereas the two lower-level resistance strains M1 and M2 carried wild-type alleles of *mmpL3* (Table 1). Mutant selection was also performed with *Mycobacterium bovis* BCG (ATCC 35734). A total of 10<sup>8</sup> bacteria were plated on agar containing SIMBL at 2× MIC<sub>90</sub> (2 μM) resulting in one strain, B1, with a 4-fold increased MIC<sub>90</sub> (Table 1). Sequencing of *mmpL3* in B1 also revealed a wild-type allele. To determine the mechanism underlying this low-level resistance not associated with *MmpL3*, the two *M. tuberculosis* strains M1 and M2 and the *M. bovis* BCG strain B1 were subjected to whole-genome sequencing as described previously (5, 7). All three strains harbored mutations in *mmpR5* encoding a nonessential transcriptional repressor (Table 1) (8, 9). The polymorphisms identified in *mmpR5* were verified by targeted Sanger sequencing using the reported primers 5′-GCACGCTTGAGAGTTCC-3′ and 5′-CGCCGTCTTGCTCGC-3′ (10). Two resistant strains showed missense mutations in the DNA-binding domain (A202G/S68G in M1) and the dimerization domain (G73T/G25C in M2) of *MmpR5*, respectively (Table 1) (8). The third strain showed a frameshift mutation (Ins68T in B1) in the N-terminal part of *MmpR5*, leading to a truncated product devoid of both domains (Table 1) (8). The nature and location of the observed resistance mutations in the *MmpR5* protein suggest that they may affect its function as a DNA-binding repressor.

*MmpR5* was reported to repress expression of its neighboring, divergently transcribed siderophore transporter and multisubstrate efflux pump gene *mmpL5* (mycobacterial membrane protein large 5) and is hence named *MmpR5* (mycobacterial membrane protein repressor 5) (10–16). Notably, numerous *MmpR5* mutations have

**TABLE 2** MIC<sub>90</sub> of SIMBL, bedaquiline, and isoniazid for wild type and SIMBL-resistant *M. tuberculosis* and *M. bovis* BCG strains without or with reserpine<sup>a,b</sup>

Compounds	MIC <sub>90</sub> (μM)				
	<i>M. tuberculosis</i>			<i>M. bovis</i> BCG	
	Wild type	M1	M2	Wild type	B1
Reserpine	>100	>100	>100	>100	>100
SIMBL	1.0	3.9	4.0	1.0	4.2
SIMBL + reserpine	0.6	0.6	0.6	0.5	0.5
BDQ	0.8	5.0	4.8	0.12	1.0
BDQ + reserpine <sup>c</sup>	0.08	0.15	0.15	0.02	0.04
INH	3.2	3.2	3.2	3.2	3.2
INH + reserpine	3.2	3.2	3.2	3.2	3.2

<sup>a</sup>MIC<sub>90</sub> is the concentration of drug required to inhibit 90% of bacterial growth in broth culture compared to an untreated drug-free control. Means of three independent determinations are shown. SIMBL, 9-[(6-methoxy-1-octyl-1*H*-indol-3-yl)methyl]-1,5-dioxo-9-azaspiro[5.5]undecane; BDQ, bedaquiline; INH, isoniazid. SIMBL was synthesized as described (4), other drugs were purchased from Sigma-Aldrich. Drug solutions were prepared in 100% dimethyl sulfoxide, except for reserpine, which was dissolved in deionized water.

<sup>b</sup>Efflux pump inhibitor reserpine was added at a subinhibitory concentration of 25 μM.

<sup>c</sup>As described previously, a potentiating effect of reserpine on the activity of bedaquiline was observed for wild-type bacteria (18).


been associated with mycobacterial resistance to a range of chemically and mechanistically diverse drugs, including azoles, bedaquiline, clofazimine, the ionophores nigericin and A23187 (calcimycin), thiacectazone, and imidazo[1,2-*b*][1,2,4,5]tetrazine derivatives (10, 16–28). In fact, the SIMBL resistance mutation in the DNA-binding domain of MmpR5 detected in *M. tuberculosis* M1 (A202G/S68G) is known to confer resistance to bedaquiline and clofazimine (18, 19). Resistance-conferring mutations in MmpR5 disable its transcriptional repressor function, resulting in overexpression of the MmpL5 pump and increased expulsion of drugs (10, 16–28). Consistent with this model, cotreatment of MmpR5 mutants overexpressing MmpL5 with drugs and the efflux pump inhibitor reserpine reverted resistance to bedaquiline (18).

We hypothesized that a similar MmpL5-mediated mechanism of resistance may also underly the 4-fold resistance of mycobacteria to SIMBL. To examine this hypothesis, we first tested the prediction that SIMBL resistance due to MmpR5 mutations should be phenotypically reverted by the efflux pump inhibitor reserpine as observed for bedaquiline (18). We cotreated the SIMBL-resistant strains M1, M2, and B1 with SIMBL and reserpine and observed that reserpine indeed restored wild-type susceptibility of all three MmpR5 mutant strains (Table 2).

Next, we tested the prediction that M1, M2, and B1 should display cross-resistance to other drugs subject to the MmpR5-MmpL5 resistance mechanism and chose bedaquiline as our test compound (16, 18–25). The MIC<sub>90</sub> of bedaquiline against all three mutants was 6- to 8-fold higher compared to the wild type (Table 2), thus demonstrating cross-resistance. Consistent with previous reports, resistance to bedaquiline was also phenotypically reversible by cotreatment with reserpine (Table 2) (18). In contrast, susceptibility to isoniazid was not altered in SIMBL/bedaquiline-resistant M1, M2, and B1 strains (Table 2) (16), suggesting that the observed effects are drug specific and not due to general drug resistance caused by MmpR5 mutations.

Finally, we tested the prediction that mutations in MmpR5 should increase the transcript level of the efflux pump gene *mmpL5*. Total RNA was extracted from *M. bovis* BCG B1 and subjected to quantitative reverse transcription-PCR analysis using 16S rRNA as the internal invariant control as described (29, 30). Compared to wild-type *M. bovis* BCG, B1 showed a more than 50-fold increase in *mmpL5* mRNA level (Fig. 1), suggesting derepression of the pump gene *mmpL5* in the MmpR5 mutant background.

In conclusion, we report the identification of a pump-based resistance mechanism to the spiroketal indolyl Mannich base lead SIMBL (9-[(6-methoxy-1-octyl-1*H*-indol-3-yl)methyl]-1,5-dioxo-9-azaspiro[5.5]undecane). This resistance mechanism arises from mutations in the transcriptional repressor MmpR5, resulting in the overexpression of



**FIG 1** Effect of SIMBL resistance mutations in *MmpR5* on *mmpL5* mRNA level. Fold change in transcript level of *mmpL5* in SIMBL-resistant *M. bovis* BCG B1 strain compared to that of the wild-type strain is shown. Transcript levels were measured by quantitative reverse transcription-PCR analysis and normalized against the internal invariant control 16S rRNA (29, 30). Mean values and standard deviations from triplicate determinations are shown. Consistent with previous reports, mutations in *MmpR5* also resulted in upregulation of *mmpR5* itself due to the gene's autoregulation (10, 16, 28). Primers used in quantitative PCR were 5'-ATGACGGCCTTCGGGTGTAA-3' and 5'-CGGCTGCTGGCACGTAGTTG-3' for 16S rRNA, 5'-GA CCAACCTGCTCGTG-3' and 5'-CGCCGAACATGGTGTA-3' for *mmpL5*, and 5'-AATGCCCGATGCTGAT-3' and 5'-CTGCAGTTCGGCCATTG-3' for *mmpR5* (10, 30).

the efflux pump *MmpL5*. *MmpL5*-mediated resistance has been reported for multiple antimycobacterials (10, 16–28). Thus, our finding adds SIMBL to the growing list of putative substrates of the *MmpL5* efflux pump. SIMBL is the first membrane-anchored agent and the first *MmpL3* binding inhibitor subject to this pump-based resistance mechanism in *M. tuberculosis*.

## ACKNOWLEDGMENTS

Funding was provided by the Ministry of Health National Medical Research Council (Singapore) (NMRC/TCR/011-NUHS/2014) and the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (USA) (R01AI132374) to T.D., and the Ministry of Education Academic Research Fund (Singapore) (R148000234114 and R148000286114) to M.-L.G. This work is part of the Singapore Program of Research Investigating New Approaches to Treatment of Tuberculosis (SPRINT-TB; [www.sprinttb.org](http://www.sprinttb.org)) led by Nick Paton. We thank the School of Medicine BSL3 core facility for support. M.L. gratefully acknowledges her graduate scholarship from the Ministry of Education Singapore.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Conceptualization, M.L., M.-L.G., and T.D.; investigation, M.L. and S.A.N.; writing, M.L., M.-L.G., and T.D.; review and editing, all authors; funding acquisition, M.-L.G. and T.D.; supervision, M.-L.G. and T.D.

We declare no competing interests.

## REFERENCES

- Hurdle JG, O'Neill AJ, Chopra I, Lee RE. 2011. Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. *Nat Rev Microbiol* 9:62–75. <https://doi.org/10.1038/nrmicro2474>.
- Chen H, Nyantakyi SA, Li M, Gopal P, Aziz DB, Yang T, Moreira W, Gengenbacher M, Dick T, Go M-L. 2018. The mycobacterial membrane: a novel target space for anti-tubercular drugs. *Front Microbiol* 9:1627. <https://doi.org/10.3389/fmicb.2018.01627>.
- Yang T, Moreira W, Nyantakyi SA, Chen H, Aziz DB, Go M-L, Dick T. 2017. Amphiphilic indole derivatives as antimycobacterial agents: structure-activity relationships and membrane targeting properties. *J Med Chem* 60:2745–2763. <https://doi.org/10.1021/acs.jmedchem.6b01530>.
- Nyantakyi SA, Li M, Gopal P, Zimmerman M, Dartois V, Gengenbacher M, Dick T, Go M-L. 2018. Indolyl azaspiroketal Mannich bases are potent antimycobacterial agents with selective membrane permeabilizing effects and *in vivo* activity. *J Med Chem* 61:5733–5750. <https://doi.org/10.1021/acs.jmedchem.8b00777>.
- Li M, Phua ZY, Xi Y, Xu Z, Nyantakyi SA, Li W, Jackson M, Wong MW, Lam Y, Chng S-S, Go M-L, Dick T. 2020. Potency increase of spiroketal analogs of membrane inserting indolyl Mannich base antimycobacterials is due to acquisition of *MmpL3* inhibition. *ACS Infect Dis* 6:1882–1893. <https://doi.org/10.1021/acscinfecdis.0c00121>.
- Li M, Nyantakyi SA, Gopal P, Aziz DB, Dick T, Go M-L. 2017. Indolylalkyl-triphenylphosphonium analogues are membrane-depolarizing mycobactericidal agents. *ACS Med Chem Lett* 8:1165–1170. <https://doi.org/10.1021/acsmchemlett.7b00287>.
- Yee M, Klinzing D, Wei J-R, Gengenbacher M, Rubin EJ, Dick T. 2017. Draft genome sequence of *Mycobacterium abscessus* Bamboo. *Genome Announc* 5:e00388-17. <https://doi.org/10.1128/genomeA.00388-17>.
- Radhakrishnan A, Kumar N, Wright CC, Chou T-H, Tringides ML, Bolla JR, Lei H-T, Rajashankar KR, Su C-C, Purdy GE, Yu EW. 2014. Crystal structure of the transcriptional regulator Rv0678 of *Mycobacterium tuberculosis*. *J Biol Chem* 289:16526–16540. <https://doi.org/10.1074/jbc.M113.538959>.

9. Richard M, Gutiérrez AV, Viljoen AJ, Ghigo E, Blaise M, Kremer L. 2018. Mechanistic and structural insights into the unique TetR-dependent regulation of a drug efflux pump in *Mycobacterium abscessus*. *Front Microbiol* 9:649. <https://doi.org/10.3389/fmicb.2018.00649>.
10. Milano A, Pasca MR, Provvedi R, Lucarelli AP, Manina G, Ribeiro A, Manganelli R, Riccardi G. 2009. Azole resistance in *Mycobacterium tuberculosis* is mediated by the MmpS5–MmpL5 efflux system. *Tuberculosis (Edinb)* 89:84–90. <https://doi.org/10.1016/j.tube.2008.08.003>.
11. Viljoen A, Dubois V, Girard-Misguich F, Blaise M, Herrmann JL, Kremer L. 2017. The diverse family of MmpL transporters in mycobacteria: from regulation to antimicrobial developments. *Mol Microbiol* 104:889–904. <https://doi.org/10.1111/mmi.13675>.
12. Briffotiaux J, Huang W, Wang X, Gicquel B. 2017. MmpS5/MmpL5 as an efflux pump in *Mycobacterium* species. *Tuberculosis (Edinb)* 107:13–19. <https://doi.org/10.1016/j.tube.2017.08.001>.
13. Wells RM, Jones CM, Xi Z, Speer A, Danilchanka O, Doornbos KS, Sun P, Wu F, Tian C, Niederweis M. 2013. Discovery of a siderophore export system essential for virulence of *Mycobacterium tuberculosis*. *PLoS Pathog* 9:e1003120. <https://doi.org/10.1371/journal.ppat.1003120>.
14. Sandhu P, Akhter Y. 2017. Siderophore transport by MmpL5–MmpS5 protein complex in *Mycobacterium tuberculosis*. *J Inorg Biochem* 170: 75–84. <https://doi.org/10.1016/j.jinorgbio.2017.02.013>.
15. Lamichhane G, Tyagi S, Bishai WR. 2005. Designer arrays for defined mutant analysis to detect genes essential for survival of *Mycobacterium tuberculosis* in mouse lungs. *Infect Immun* 73:2533–2540. <https://doi.org/10.1128/IAI.73.4.2533-2540.2005>.
16. Hartkoorn RC, Uplekar S, Cole ST. 2014. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 58:2979–2981. <https://doi.org/10.1128/AAC.00037-14>.
17. Iøerger TR, O'Malley T, Liao R, Guinn KM, Hickey MJ, Mohaideen N, Murphy KC, Boshoff HIM, Mizrahi V, Rubin EJ, Sassetti CM, Barry CE, Sherman DR, Parish T, Sacchettini JC. 2013. Identification of new drug targets and resistance mechanisms in *Mycobacterium tuberculosis*. *PLoS One* 8:e75245. <https://doi.org/10.1371/journal.pone.0075245>.
18. Andries K, Vilellas C, Coeck N, Thys K, Gevers T, Vranckx L, Lounis N, de Jong BC, Koul A. 2014. Acquired resistance of *Mycobacterium tuberculosis* to bedaquiline. *PLoS One* 9:e102135. <https://doi.org/10.1371/journal.pone.0102135>.
19. Zhang S, Chen J, Cui P, Shi W, Zhang W, Zhang Y. 2015. Identification of novel mutations associated with clofazimine resistance in *Mycobacterium tuberculosis*. *J Antimicrob Chemother* 70:2507–2510. <https://doi.org/10.1093/jac/dkv150>.
20. Somoskovi A, Bruderer V, Hömke R, Bloemberg GV, Böttger EC. 2015. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment. *Eur Respir J* 45:554–557. <https://doi.org/10.1183/09031936.00142914>.
21. Vilellas C, Coeck N, Meehan CJ, Lounis N, de Jong B, Rigouts L, Andries K. 2017. Unexpected high prevalence of resistance-associated *Rv0678* variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline. *J Antimicrob Chemother* 72:684–690. <https://doi.org/10.1093/jac/dkw502>.
22. Pang Y, Zong Z, Huo F, Jing W, Ma Y, Dong L, Li Y, Zhao L, Fu Y, Huang H. 2017. *In vitro* drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug-resistant tuberculosis in Beijing, China. *Antimicrob Agents Chemother* 61:e00900-17. <https://doi.org/10.1128/AAC.00900-17>.
23. Ismail N, Peters RP, Ismail NA, Omar SV. 2019. Clofazimine exposure *in vitro* selects efflux pump mutants and bedaquiline resistance. *Antimicrob Agents Chemother* 63:e02141-18. <https://doi.org/10.1128/AAC.02141-18>.
24. Alexander DC, Vasireddy R, Vasireddy S, Philley JV, Brown-Elliott BA, Perry BJ, Griffith DE, Benwill JL, Cameron AD, Wallace RJ. 2017. Emergence of *mmpT5* variants during bedaquiline treatment of *Mycobacterium intracellulare* lung disease. *J Clin Microbiol* 55:574–584. <https://doi.org/10.1128/JCM.02087-16>.
25. Li B, Ye M, Guo Q, Zhang Z, Yang S, Ma W, Yu F, Chu H. 2018. Determination of MIC distribution and mechanisms of decreased susceptibility to bedaquiline among clinical isolates of *Mycobacterium abscessus*. *Antimicrob Agents Chemother* 62:e00175-18. <https://doi.org/10.1128/AAC.00175-18>.
26. Huang W, Briffotiaux J, Wang X, Liu L, Hao P, Cimino M, Buchieri MV, Namouchi A, Ainsa J-A, Gicquel B. 2017. Ionophore A23187 shows anti-tuberculosis activity and synergy with tebipenem. *Tuberculosis (Edinb)* 107:111–118. <https://doi.org/10.1016/j.tube.2017.09.001>.
27. Halloum I, Viljoen A, Khanna V, Craig D, Bouchier C, Brosch R, Coxon G, Kremer L. 2017. Resistance to thiacetazone derivatives active against *Mycobacterium abscessus* involves mutations in the MmpL5 transcriptional repressor MAB\_4384. *Antimicrob Agents Chemother* 61:e02509-16. <https://doi.org/10.1128/AAC.02509-16>.
28. Maslov DA, Shur KV, Vatlin AA, Danilenko VN. 2020. MmpS5–MmpL5 transporters provide *Mycobacterium smegmatis* resistance to imidazo [1,2-b][1,2,4,5]tetrazines. *Pathogens* 9:166. <https://doi.org/10.3390/pathogens9030166>.
29. Aziz DB, Go ML, Dick T. 2020. Rifabutin suppresses inducible clarithromycin resistance in *Mycobacterium abscessus* by blocking induction of *whiB7* and *erm41*. *Antibiotics* 9:72. <https://doi.org/10.3390/antibiotics9020072>.
30. Badillo-López C, González-Mejía A, Helguera-Repetto AC, Salas-Rangel LP, Rivera-Gutiérrez S, Cerna-Cortés JF, González-y-Merchad JA. 2010. Differential expression of *dnaA* and *dosR* genes among members of the *Mycobacterium tuberculosis* complex under oxic and hypoxic conditions. *Int Microbiol* 13:9–13. <https://doi.org/10.2436/20.1501.01.106>.